3,471 research outputs found
DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder
Dentatorubral–pallidoluysian atrophy (DRPLA) is a rare neurodegenerative disorder caused by CAG repeat expansions in the atrophin-1 gene and is inherited in an autosomal dominant fashion. There are currently no disease-modifying treatments available. The broad development of therapies for DRPLA, as well as other similar rare diseases, has hit a roadblock due to the rarity of the condition and the wide global distribution of patients and families, consequently inhibiting biomarker development and therapeutic research. Considering the shifting focus towards diverse populations, widespread genetic testing, rapid advancements in the development of clinical and wet biomarkers for Huntington’s disease (HD), and the ongoing clinical trials for antisense oligonucleotide (ASO) therapies, the prospect of developing effective treatments in rare disorders has completely changed. The awareness of the HD ASO program has prompted global collaboration for rare disorders in natural history studies and the development of biomarkers, with the eventual goal of undergoing treatment trials. Here, we discuss DRPLA, which shares similarities with HD, and how in this and other repeat expansion disorders, neurogenetics groups like ours at UCL are gearing up for forthcoming natural history studies to accelerate future ASO treatment trials to hopefully emulate the progress seen in HD
Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review
RATIONALE: Frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB) are two common forms of neurodegenerative dementia, subsequent to Alzheimer's disease (AD). AD is the only dementia that includes clinically validated cerebrospinal fluid (CSF) biomarkers in the diagnostic criteria. FTD and DLB often overlap with AD in their clinical and pathological features, making it challenging to differentiate between these conditions. AIM: This systematic review aimed to identify if novel fluid biomarkers are useful in differentiating FTD and DLB from AD. Increasing the certainty of the differentiation between dementia subtypes would be advantageous clinically and in research. METHODS: PubMed and Scopus were searched for studies that quantified and assessed diagnostic accuracy of novel fluid biomarkers in clinically diagnosed patients with FTD or DLB, in comparison to patients with AD. Meta-analyses were performed on biomarkers that were quantified in 3 studies or more. RESULTS: The search strategy yielded 614 results, from which, 27 studies were included. When comparing bio-fluid levels in AD and FTD patients, neurofilament light chain (NfL) level was often higher in FTD, whilst brain soluble amyloid precursor protein β (sAPPβ) was higher in patients with AD. When comparing bio-fluid levels in AD and DLB patients, α-synuclein ensued heterogeneous findings, while the noradrenaline metabolite (MHPG) was found to be lower in DLB. Ratios of Aβ42/Aβ38 and Aβ42/Aβ40 were lower in AD than FTD and DLB and offered better diagnostic accuracy than raw amyloid-β (Aβ) concentrations. CONCLUSIONS: Several promising novel biomarkers were highlighted in this review. Combinations of fluid biomarkers were more often useful than individual biomarkers in distinguishing subtypes of dementia. Considering the heterogeneity in methods and results between the studies, further validation, ideally with longitudinal prospective designs with large sample sizes and unified protocols, are fundamental before conclusions can be finalised
The genetics of intellectual disability: advancing technology and gene editing [version 1; peer review: 2 approved]
Intellectual disability (ID) is a neurodevelopmental condition affecting 1–3% of the world’s population. Genetic factors play a key role causing the congenital limitations in intellectual functioning and adaptive behavior. The heterogeneity of ID makes it more challenging for genetic and clinical diagnosis, but the advent of large-scale genome sequencing projects in a trio approach has proven very effective. However, many variants are still difficult to interpret. A combined approach of next-generation sequencing and functional, electrophysiological, and bioinformatics analysis has identified new ways to understand the causes of ID and help to interpret novel ID-causing genes. This approach offers new targets for ID therapy and increases the efficiency of ID diagnosis. The most recent functional advancements and new gene editing techniques involving the use of CRISPR–Cas9 allow for targeted editing of DNA in in vitro and more effective mammalian and human tissue-derived disease models. The expansion of genomic analysis of ID patients in diverse and ancient populations can reveal rare novel disease-causing genes
A Review of Copy Number Variants in Inherited Neuropathies
The rapid development in the last 10-15 years of microarray technologies, such as oligonucleotide
array Comparative Genomic Hybridization (CGH) and Single Nucleotide Polymorphisms
(SNP) genotyping array, has improved the identification of fine chromosomal structural variants, ranging
in length from kilobases (kb) to megabases (Mb), as an important cause of genetic differences
among healthy individuals and also as disease-susceptibility and/or disease-causing factors. Structural
genomic variations due to unbalanced chromosomal rearrangements are known as Copy-Number
Variants (CNVs) and these include variably sized deletions, duplications, triplications and translocations.
CNVs can significantly contribute to human diseases and rearrangements in several dosagesensitive
genes have been identified as an important causative mechanism in the molecular aetiology
of Charcot-Marie-Tooth (CMT) disease and of several CMT-related disorders, a group of inherited
neuropathies with a broad range of clinical phenotypes, inheritance patterns and causative genes. Duplications
or deletions of the dosage-sensitive gene PMP22 mapped to chromosome 17p12 represent
the most frequent causes of CMT type 1A and Hereditary Neuropathy with liability to Pressure Palsies
(HNPP), respectively. Additionally, CNVs have been identified in patients with other CMT types
(e.g., CMT1X, CMT1B, CMT4D) and different hereditary poly- (e.g., giant axonal neuropathy) and
focal- (e.g., hereditary neuralgic amyotrophy) neuropathies, supporting the notion of hereditary peripheral
nerve diseases as possible genomic disorders and making crucial the identification of fine
chromosomal rearrangements in the molecular assessment of such patients. Notably, the application of
advanced computational tools in the analysis of Next-Generation Sequencing (NGS) data has emerged
in recent years as a powerful technique for identifying a genome-wide scale complex structural variants
(e.g., as the ones resulted from balanced rearrangements) and also smaller pathogenic (intragenic)
CNVs that often remain beyond the detection limit of most conventional genomic microarray analyses;
in the context of inherited neuropathies where more than 70 disease-causing genes have been
identified to date, NGS and particularly Whole-Genome Sequencing (WGS) hold the potential to reduce
the number of genomic assays required per patient to reach a diagnosis, analyzing with a single
test all the Single Nucleotide Variants (SNVs) and CNVs in the genes possibly implicated in this
heterogeneous group of disorders
PRUNE1: a disease-causing gene for secondary microcephaly
In their Letter to the Editor, Karakaya et al. (2017) present
an interesting case report describing the clinical course
involving secondary microcephaly of a 3-year-old Turkish
boy found to be homozygous for a frameshift mutation in
PRUNE1 identified through whole exome sequencing. The
child presented with congenital hypotonia, contractures and
global developmental delay with respiratory insufficiency
and seizures developing in the first year of life. The authors
note that the affected child’s head circumference plotted on
the 75th centile at birth, and that by 38 months of age he
had developed microcephaly. Neuroimaging at 14 months
revealed cerebral and cerebellar atrophy consistent with
other patients described with Prune syndrome (Karaca
et al., 2015; Costain et al., 2017; Zollo et al., 2017).
Although the child had abnormal neurology from birth,
there was a period of early developmental regression.
Peripheral spasticity in the lower extremities and optic atrophy
were not documented until 38 months. In addition to
the PRUNE1 variant, Karakaya et al. also identified a
second homozygous variant in the CCDC14 gene in the
Turkish child’s whole exome sequencing data that, while
listed to have an allele count of 108 in the current Genome
Aggregation Database (gnomAD) release, is notably absent
in homozygous fashion (Lek et al., 2016). CCDC14 is
known to be expressed in human brain, reported to negatively
regulate centriole duplication and interact with proteins
previously associated with primary microcephaly
(Firat-Karalar et al., 2014). Thus, while it seems likely
that the homozygous PRUNE1 variant is primarily responsible
for the clinical presentation in the Turkish child, it is
impossible to determine whether there may be any phenotypical
contribution from this additional homozygous
sequence variant.
Recently, Costain et al. (2017) described a homozygous
consensus splice site variant in PRUNE1 (c.521-2A4G;
NM_021222.1) in a 2-year-old Oji-Cre male who presented
with congenital hypotonia and talipes, whose head circumference
was large at birth ( +3 standard deviations), but by
2 years and 2 months plotted on the 50th centile, with a
weight and height on the 95th and 75th centiles, respectively.
However, it should be noted that the child’s father
is macrocephalic ( +4 standard deviations), the published
clinical photographs at 2 years 5 months of age illustrate
bitemporal narrowing, a sloping forehead and large ears,
consistent with a developing microcephaly, and neuroimaging revealed cortical and cerebellar atrophy. He
developed respiratory insufficiency shortly after birth, and
infantile spasms in the first year of life (Costain et al., 2017).
It remains to be determined how the phenotypical outcomes
stemming from proposed loss-of-function mutations
defined by Karakaya et al. and Costain et al., relate to
missense mutations published by Karaca et al. and also
Zollo et al., which are likely to involve at least partial
gain-of-function outcomes in PRUNE1 activity. However,
as more cases are investigated and published, the phenotype
associated with autosomal recessive Prune neurodevelopmental
disorder, and the functional outcomes of
PRUNE1 mutation, are becoming clearer. It is now apparent
that while some patients have a small head at birth and
others a head circumference in the normal range, the key
component of the microcephaly is that it is progressive, and
associated with characteristic neuroimaging findings with a
thin or hypoplastic corpus callosum and cortical and cerebellar
atrophy developing in early childhood. Although all
patients with Prune syndrome described to date are neurologically
impaired from birth, there also appears to be a
neurodegenerative component with progression of the disorder.
In our manuscript, we described clinical overlap of
Prune syndrome with the neurodegenerative condition associated
with homozygous mutations in TBCD (Zollo et al.,
2017). TBCD encodes one of the five tubulin-specific chaperones
that are required for a/b-tubulin de novo heterodimer
formation and the disorder is characterized by
developmental regression, seizures, optic atrophy and secondary
microcephaly, cortical atrophy with delayed myelination,
cerebellar atrophy and thinned corpus callosum
(Edvardson et al., 2016; Flex et al., 2016; Miyake et al.,
2016; Pode-Shakked et al., 2017). The neurodegenerative
phenotype documented in the Turkish child by Karakaya
et al. further demonstrates the similarities with the TBCD
disorder and Prune syndrome, and confirms optic atrophy
to be a feature of Prune syndrome. Interestingly, it is also
becoming clear that respiratory insufficiency is a common
feature of Prune syndrome, having been documented by
Karakaya et al. and in the Oji-Cre child, as well as the
youngest affected Omani child described in our manuscript
R1352Q CACNA1A Variant in a Patient with Sporadic Hemiplegic Migraine, Ataxia, Seizures and Cerebral Oedema: A Case Report
Mutations in the CACNA1A gene show a wide range of neurological phenotypes including hemiplegic migraine, ataxia, mental retardation and epilepsy. In some cases, hemiplegic migraine attacks can be triggered by minor head trauma and culminate in encephalopathy and cerebral oedema. A 37-year-old male without a family history of complex migraine experienced hemiplegic migraine attacks from childhood. The attacks were usually triggered by minor head trauma, and on several occasions complicated with encephalopathy and cerebral oedema. Genetic testing of the proband and unaffected parents revealed a de novo heterozygous nucleotide missense mutation in exon 25 of the CACNA1A gene (c.4055G>A, p.R1352Q). The R1352Q CACNA1A variant shares the phenotype with other described CACNA1A mutations and highlights the interesting association of trauma as a precipitant for hemiplegic migraine. Subjects with early-onset sporadic hemiplegic migraine triggered by minor head injury or associated with seizures, ataxia or episodes of encephalopathy should be screened for mutations. These patients should also be advised to avoid activities that may result in head trauma, and anticonvulsants should be considered as prophylactic migraine therapy
What are the experiences of adults returning to work following recovery from Guillain-Barré syndrome? An interpretative phenomenological analysis
This is the author's accepted manuscript. The final published article is available from the link below. Copyright @ 2009 Informa UK Ltd.Purpose. Guillain-Barré syndrome (GBS) is a transient inflammatory disorder affecting peripheral nerves, characterised by weakness and numbness in limbs, upper body and face. Residual problems affect a large minority, and complicate return to work. This qualitative study explored the experiences of people who returned to work following their diagnosis of GBS and recovery, to gain insight into factors that facilitated or inhibited this process.
Method. Five people participated in in-depth interviews. Individual and common experiences were explored through interpretative phenomenological analysis.
Findings. Three recurring themes are presented: the perceived value of work; losing and recovering a familiar identity at work; and dilemmas around using support and adaptations at work. Certain individual issues also emerged but are beyond the scope of this article. Participants tended to measure their recovery in terms of returning to work yet continued to experience certain physical and psychosocial difficulties at work related to GBS, which required active coping strategies. Limited public awareness of GBS was perceived as a hindrance when returning to work.
Conclusion. This study provides a rich account of the experiences that people encounter returning to work following GBS. Rehabilitation specialists may offer more effective preparation for this process, drawing upon the issues identified
Severe axonal neuropathy is a late manifestation of SPG11
Complex hereditary spastic paraplegia (HSP) is a clinically heterogeneous group of disorders usually inherited in an autosomal recessive manner. In the past, complex recessive spastic paraplegias have been frequently associated with SPG11 mutations but also with defects in SPG15, SPG7 and a handful of other rare genes. Pleiotropy exists in HSP genes, exemplified in the recent association of SPG11 mutations with CMT2. In this study, we performed whole exome sequence analysis and identified two siblings with novel compound heterozygous frameshift SPG11 mutations. The mutations segregated with disease were not present in control databases and analysis of skin fibroblast derived mRNA indicated that the SPG11 truncated mRNA species were not degraded significantly by non-sense mediated mRNA decay. These siblings had severe early-onset spastic paraplegia but later in their disease developed severe axonal neuropathy, neuropathic pain and blue/black foot discolouration likely caused by a combination of the severe neuropathy with autonomic dysfunction and peripheral oedema. We also identified a similar late-onset axonal neuropathy in a Cypriot SPG11 family. Although neuropathy is occasionally present in SPG11, in our SPG11 patients reported here it was particularly severe, highlighting the association of axonal neuropathy with SPG11 and the late manifestation of axonal peripheral nerve damage
Using human induced pluripotent stem cells to model cerebellar disease: Hope and hype
The cerebellum forms a highly ordered and indispensible component of motor function within the adult neuraxis, consisting of several distinct cellular subtypes. Cerebellar disease, through a variety of genetic and acquired causes, results in the loss of function of defined subclasses of neurons, and remains a significant and untreatable health care burden. The scarcity of therapies in this arena can partially be explained by unresolved disease mechanisms due to inaccessibility of human cerebellar neurons in a relevant experimental context where initiating disease mechanisms could be functionally elucidated, or drug screens conducted. In this review we discuss the potential promise of human induced pluripotent stem cells (hiPSCs) for regenerative neurology, with a particular emphasis on in vitro modelling of cerebellar degeneration. We discuss progress made thus far using hiPSC-based models of neurodegeneration, noting the relatively slower pace of discovery made in modelling cerebellar dysfunction. We conclude by speculating how strategies attempting cerebellar differentiation from hiPSCs can be refined to allow the generation of accurate disease models. This in turn will permit a greater understanding of cerebellar pathophysiology to inform mechanistically rationalised therapies, which are desperately needed in this field
- …